id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263882-s5oxr6es	Najar Nobar, Niloufar	Patients with specific skin disorders who are affected by COVID‐19: what do experiences say about management strategies? : A systematic review	2020-06-18		.txt	text/plain	2543	145	41	It seems that in patients with any severe and serious dermatologic disorders, under treatment with systemic agents, if there is not any suspicion about concurrent infection or any high risk exposures, not only it is not recommend to cessation therapy but only emphasize that these drugs could prevent disease flare-up and control cytokine storm that both in a negative direction, affect the COVID-19 course (41) (42) (43) (44) (45) (46) (47) (48) . So in this systematic review we focused on specific patient groups with a dermatologic disorder (usually under therapy) that concomitantly have been infected by the new corona virus and summed up their data in all aspects of underlying and infectious disease course and management. At the time of the COVID-19, the biologic agents were discontinued except for one case (which was treated with Guselkumab) but the patients did not report any severe exacerbation of their underlying dermatologic disease despite treatment discontinuation.	./cache/cord-263882-s5oxr6es.txt	./txt/cord-263882-s5oxr6es.txt